Formulation and Evaluation of Bilayer tablet of Lisinopril and Gliclazide for Diabetic Hypertension
Abstract
Bilayer tablet technology offers an effective approach for the management of chronic diseases requiring combination therapy. The present study focuses on the formulation and evaluation of bilayer tablets containing Lisinopril and Gliclazide for the treatment of hypertension associated with type 2 diabetes mellitus. The objective of the study was to develop a formulation providing immediate release of Lisinopril for rapid antihypertensive action and sustained release of Gliclazide for prolonged glycemic control. Bilayer tablets were prepared by direct compression method using different concentrations of superdisintegrants and matrix forming polymers such as Hydroxypropyl Methylcellulose (HPMC), Hydroxypropyl Cellulose (HPC), Hydroxyethyl Cellulose (HEC) and Ethyl Cellulose (EC). Precompression parameters including angle of repose, bulk density, Carr’s index and Hausner ratio were found within acceptable pharmacopeial limits, indicating good flowability and compressibility of powder blends. Postcompression evaluation showed satisfactory hardness (3.40–3.83 kg/cm²), friability below 1%, uniform thickness and acceptable drug content. The optimized immediate release formulation CC8 showed 96.65% drug release of Lisinopril within 30 min, whereas sustained release formulations prolonged the release of Gliclazide for more than 8 h following zero-order kinetics with super case-II transport mechanism. The optimized bilayer tablet formulation BCC8F14 exhibited satisfactory physicochemical properties and desired bimodal drug release profile. Stability studies revealed no significant changes under accelerated conditions. The developed bilayer tablet formulation may improve therapeutic efficacy, patient compliance and effective management of diabetic hypertension.
Keywords: Bilayer tablet, Lisinopril, Gliclazide, Immediate release, Sustained release, Diabetic, Hypertension.
Keywords:
Bilayer tablet, Gliclazide , lisinopril, Immediate release, Sustained release, Diabetic, HypertensionDOI
https://doi.org/10.22270/jddt.v16i6.7796References
1. Mishra P, Sharma PK, Malviya R, A review on bilayer tablets-an emerging trend, J Drug Deliv Ther 2014;4(4):110-114. https://doi.org/10.22270/jddt.v4i4.900
2. Abebe A, Akseli I, Sprockel O, Kottala N, Cuitiño AM, Review of bilayer tablet technology, Int J Pharm, 2014;461(1-2):549-558. https://doi.org/10.1016/j.ijpharm.2013.12.028 PMid:24370841
3. Sweetman SC Martindale: The Complete Drug Reference, 36th ed London: Pharmaceutical Press; 2009.
4. Singh AK, Singh R, Is gliclazide a sulfonylurea with difference? Expert Rev Clin Pharmaco, 2016;9(6):839-851. https://doi.org/10.1586/17512433.2016.1159512 PMid:26924475
5. Soni N, Joshi D, Jain V, Pal P, Applications of bilayer tablet technology: a review, J Drug Deliv Ther, 2022;12(1):222-227. https://doi.org/10.22270/jddt.v12i1.5206
6. Kaur T, Gill B, Kumar S, Gupta GD, Bilayer tablets: a review, Int Res J Pharm, 2013;4(4):1-5. https://doi.org/10.7897/2230-8407.04401
7. Aleti R, Rao SB, Jagirapu B, et al, Formulation and evaluation of metformin hydrochloride and gliclazide sustained release bilayer tablets, Int J Appl Pharm, 2021;13(5):214-220. https://doi.org/10.22159/ijap.2021v13i5.41339
8. Singh A, Das S, Gupta S, Ghosh, Challenges in bilayer tablet formulation: a review, J Drug Deliv Ther, 2021;11(4-S):171-175. https://doi.org/10.22270/jddt.v11i4-S.4922
9. Shiyani B, Gattani S, Surana S, Formulation and evaluation of bi-layer tablet of metoclopramide hydrochloride and ibuprofen, AAPS PharmSciTech, 2008;9(3):818-827. PMid:18612830 PMCid:PMC2977017 https://doi.org/10.1208/s12249-008-9116-y
10. Panchal HA, Tiwari AK. Bilayer tablet technology for controlled drug delivery system: a review, J Pharm Res, 2012;5(7):3855-3858.
Published
Abstract Display: 0 
PDF Downloads: 0 PDF Downloads: 0 How to Cite
Issue
Section
Copyright (c) 2026 Anil B. Panchal, Gauri N. Narawade, Sampat D. Navale
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.